All In Biotech

Drug Trial Radar · NCT07673744

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

A Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Jul 1, 2028

Study completion Jan 1, 2030

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.

Conditions

  • Myasthenia Gravis

Interventions

  • UblituximabDrug

    Administered as an IV infusion.

  • PlaceboDrug

    Administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of a Clinical Worsening EventTime frame: Up to Week 24

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Colorado Springs, Colorado · Recruiting

  • TG Therapeutics Investigational Trial Site

    Colorado Springs, Colorado · Recruiting

  • TG Therapeutics Investigational Trial Site

    Clearwater, Florida · Recruiting

  • TG Therapeutics Investigational Trial Site

    Maitland, Florida · Recruiting

  • TG Therapeutics Investigational Trial Site

    Farmington Hills, Michigan · Recruiting

  • TG Therapeutics Investigational Trial Site

    New Bern, North Carolina · Recruiting

  • TG Therapeutics Investigational Trial Site

    Greenville, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.